Sinovac Receives Certificate of Approval to Distribute Panflu (H5N1) Vaccine in Hong Kong

Sinovac Receives Certificate of Approval to Distribute Panflu (H5N1) Vaccine
in Hong Kong

BEIJING, Oct. 13 /PRNewswire-Asia/ -- Sinovac Biotech Ltd.
(NYSE Amex: SVA), a leading developer and provider of vaccines in China,
announced today that its wholly-owned subsidiary, Sinovac Biotech (Hong Kong)
Ltd, has received the Certificate of Approval to distribute Panflu(TM) (H5N1),
its H5N1 (bird flu) pandemic influenza vaccine, in Hong Kong. The certificate
is valid through September 13, 2014 and thereafter will be renewable for
periods of five years at a time, subject to payment of the registration fee.
Sinovac Biotech (Hong Kong) Ltd, was established in October 2008 to focus
on registering and distributing Sinovac's vaccines in Hong Kong and seeking
vaccine R&D opportunities in Hong Kong. In the coming months, the Company
plans to submit applications in Hong Kong for approval for its Panflu.1 (H1N1)
and Anflu vaccines.
Mr. Weidong Yin, Chairman, President and CEO of Sinovac, commented, "We
are pleased to receive approval to market Panflu in Hong Kong, as it
represents an opportunity to significantly expand our market reach. In working
closely with Hong Kong officials on regulatory approval for Panflu, we have
gained knowledge about the regulatory process there and plan to submit
applications in the near future for additional vaccines, specifically Panflu.1
for swine flu and Anflu. And at the same time, Hong Kong officials have gained
an overall understanding of the quality of Sinovac's product. The approval in
Hong Kong for Panflu is a significant step in our mission to distribute our
affordable, high-quality and safe vaccines on a global basis."
About Sinovac
Sinovac Biotech Ltd. is a China-based biopharmaceutical company that
focuses on the research, development, manufacture and commercialization of
vaccines that protect against human infectious diseases. Sinovac's vaccine
products include Healive(R) (hepatitis A), Bilive(R) (combined hepatitis A and
B), and Anflu(R) (influenza). Panflu(TM), Sinovac's pandemic influenza vaccine
(H5N1), has already been approved for government stockpiling. Sinovac is
developing vaccines for enterovirus 71, universal pandemic influenza, Japanese
encephalitis, and human rabies. Its wholly owned subsidiary, Tangshan Yian, is
conducting field trials for independently developed inactivated animal rabies
vaccines.
Safe Harbor Statement
This announcement contains forward-looking statements. These statements
are made under the "safe harbor" provisions of the U.S. Private Securities
Litigation Reform Act of 1995. These forward-looking statements can be
identified by words or phrases such as "will," "expects," "anticipates,"
"future," "intends," "plans," "believes," "estimates" and similar statements.
Among other things, the business outlook and quotations from management in
this press release contain forward-looking statements. Statements that are not
historical facts, including statements about Sinovac's beliefs and
expectations, are forward-looking statements. Forward-looking statements
involve inherent risks and uncertainties. A number of important factors could
cause actual results to differ materially from those contained in any
forward-looking statement. Sinovac does not undertake any obligation to update
any forward-looking statement, except as required under applicable law.
For more information, please contact:

Company:
Helen G. Yang
Sinovac Biotech Ltd.
Tel: +86-10-8289-0088 x9871
Fax: +86-10-6296-6910
Email: info@sinovac.com

Investors:
Amy Glynn/Stephanie Carrington
The Ruth Group
Tel: +1-646-536-7023/7017
Email: aglynn@theruthgroup.com
scarrington@theruthgroup.com

Media:
Janine McCargo
The Ruth Group
Tel: +1-646-536-7033
Email: jmccargo@theruthgroup.com

SOURCE Sinovac Biotech Ltd.

Helen G. Yang of Sinovac Biotech Ltd., +86-10-8289-0088 x9871, Fax
+86-10-6296-6910, info@sinovac.com; or Investors, Amy Glynn & Sara Pellegrino,
+1-646-536-7023/7002, aglynn@theruthgroup.com, spellegrino@theruthgroup.com,
or Media, Janine McCargo, +1-656-536-7033, jmccargo@theruthgroup.com, all of
The Ruth Group